Bidirectional crosstalk between AR and epidermal growth factor receptor (EGFR) pathways further implicates therapeutic synergy, suggesting that androgen deprivation therapy (ADT), established in prostate cancer, may offer utility in AR+ TNBC either concurrently or sequentially (67–69). This evidence concerns the gene AR and prostate cancer.